Publications by authors named "I Blume"
Article Synopsis
- Identical stimuli can lead to different perceptions and responses despite being similar, highlighting variability in sensory processing.
- Research in the visual area V4 of monkeys revealed that hit trials, or successful identifications of stimulus changes, are linked to higher arousal levels, more stable eye positions, and improved decoding of stimulus identity from neural activity.
- Results showed that during hit trials, stronger neural responses, lower variability in excitatory neurons, and greater synchrony in cortical layers contributed to enhanced sensory processing at the threshold of perception.
The Sertoli cell (SC)-specific knockout (KO) of connexin43 (Cx43) was shown to be an effector of multiple histological changes in tubular morphology, resulting in germ cell loss through to a Sertoli-cell-only (SCO) phenotype and vacuolated seminiferous tubules containing SC-clusters. Our present study focused on the effects of Cx43 loss on SC ultrastructure. Using serial block-face scanning electron microscopy (SBF-SEM), we could confirm previous results.
View Article and Find Full Text PDFObjective: The technical feasibility of virtual noncontrast (VNC) images from dual-energy computed tomography (DECT) for the detection of the hyperdense artery sign (HAS) in ischemic stroke patients was investigated.
Methods: True noncontrast (TNC) scans of 60 patients either with or without HAS (n = 30 each) were investigated. Clot presence and characteristics were assessed on VNC images from DECT angiography and compared with TNC images.
A number of treatments targeting VEGF or mTOR pathways have been approved for metastatic clear cell Renal Cell Carcinoma (ccRCC), but the majority of patients show disease progression after first line therapy with a very low rate of complete or long-term responders. It has been shown that miRs may play a role in prediction of treatment response in various cancer types. The aim of our study was to identify a miR signature predictive for RCC patients' response to antiangiogenic tyrosine kinase inhibitor (TKI) treatment in the first line therapy.
View Article and Find Full Text PDF